SEC Form SC TO-I/A filed by Incyte Corp. (Amendment)

5/15/24 11:10:29 AM ET

$INCY

Biotechnology: Commercial Physical & Biological Resarch

Health Care

Get the next $INCY alert in real time by email

SC TO-I/A 1 tm2413972-11_sctoia.htm SC TO-I/A tm2413972-11_sctoia - none - 1.8750017s

As filed with the Securities and Exchange Commission on May 15, 2024

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE TO

(AMENDMENT NO. 1)

TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934

INCYTE CORPORATION

(Name of Subject Company (Issuer))

INCYTE CORPORATION

(Names of Filing Persons (Issuer and Offeror))

COMMON STOCK, $.001 PAR VALUE

(Title of Class of Securities)

45337C102

(CUSIP Number of Class of Securities)

Hervé Hoppenot
President and Chief Executive Officer
Incyte Corporation
1901 Augustine Cut-Off
Wilmington, Delaware 19803
(302) 498-6700

(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications on Behalf of Filing Persons)

With copies to:

Stanton D. Wong
Pillsbury Winthrop Shaw Pittman LLP
Four Embarcadero Center, 22nd Floor
San Fransisco, California 94111
(415) 983-1000

Stephen C. Ashley
Pillsbury Winthrop Shaw Pittman LLP
31 West 52nd Street
New York, NY 10019-6131
(212) 858-1000

☐

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. Check the appropriate boxes below to designate any transactions to which the statement relates:

☐

third-party tender offer subject to Rule 14d-1.

☒

issuer tender offer subject to Rule 13e-4.

☐

going-private transaction subject to Rule 13e-3.

☐

amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

☐

Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

☐

Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

INTRODUCTION

This Amendment No. 1 (this “Amendment”) amends and supplements the Tender Offer Statement on Schedule TO originally filed with the Securities and Exchange Commission on May 13, 2024 (the “Schedule TO”), relating to the offer by Incyte Corporation, a Delaware corporation (the “Company”), to purchase up to $1.672 billion in value of its common stock, $.001 par value, at a price not greater than $60.00 per share nor less than $52.00 per share, net to the seller in cash, less any applicable withholding taxes and without interest, upon the terms and subject to the conditions set forth in the Offer to Purchase dated May 13, 2024 (the “Offer to Purchase”), and in the related Letter of Transmittal (the “Letter of Transmittal”), copies of which were previously filed as Exhibits (a)(1)(A) and (a)(1)(B), respectively, to the Schedule TO.

The purpose of this Amendment is to file corrected versions of Exhibits (a)(1)(B) and (a)(1)(C). Only those items amended are reported in this Amendment. This Amendment should be read in conjunction with the Schedule TO, the Offer to Purchase and the Letter of Transmittal.

ITEM 12. EXHIBITS.

	Exhibit Number			Description
	(a)(1)(A)**			Offer to Purchase dated May 13, 2024.
	(a)(1)(B)*			Letter of Transmittal.
	(a)(1)(C)*			Notice of Guarantee Delivery.
	(a)(1)(D)**			Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.
	(a)(1)(E)**			Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.
	(a)(5)(A)			Press Release dated May 13, 2024 (incorporated by reference to Exhibit 99.1 to the Company’s Tender Offer Statement on Schedule TO-C filed with the SEC on May 13, 2024).
	(a)(5)(B)**			Summary Advertisement dated May 13, 2024.
	(b)			Not Applicable.
	(d)(1)			Incyte Corporation Amended and Restated 2010 Stock Incentive Plan, as amended on April 13, 2023 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed June 15, 2023).
	(d)(2)			Form of Global Stock Option Agreement for Executive Officers under the Incyte Corporation Amended and Restated 2010 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020).
	(d)(3)			Form of Global Restricted Stock Unit Award Agreement under the Incyte Corporation Amended and Restated 2010 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020).
	(d)(4)			Form of Performance Share Award Agreement under the Incyte Corporation Amended and Restated 2010 Stock Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020).
	(d)(5)			Form of Nonstatutory Stock Option Agreement for Outside Directors under the Incyte Corporation Amended and Restated 2010 Stock Incentive Plan (incorporated by reference to Exhibit 10.24 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2013).
	(d)(6)			Form of Restricted Stock Unit Award Agreement for Outside Directors under the Incyte Corporation Amended and Restated 2010 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2019).

	Exhibit Number			Description
	(d)(7)			Form of Indemnity Agreement between the Company and its directors and officers (incorporated by reference to Exhibit 10.5 to the Company’s Registration Statement on Form S-1 (File No. 33 68138)).
	(d)(8)			1997 Employee Stock Purchase Plan of Incyte Corporation, as amended on April 13, 2023 (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed June 15, 2023).
	(d)(9)			Form of Employment Agreement between the Company and Barry P. Flannelly (effective as of August 11, 2014), Christiana Stamoulis (effective as of February 11, 2019), Steven H. Stein (effective as of March 2, 2015), Vijay K. Iyengar (effective as of May 9, 2016), Pablo J. Cagnoni (effective as of June 7, 2023) and Sheila A. Denton (effective as of October 2, 2023) (incorporated by reference to Exhibit 10.14 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2012).
	(d)(10)			Form of Amended and Restated Employment Agreement, effective as of April 18, 2012, between the Company and Paula J. Swain (incorporated by reference to Exhibit 10.14 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2012).
	(d)(11)			Offer of Employment Letter, dated December 14, 2018, from the Company to Christiana Stamoulis (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019).
	(d)(12)			Amended and Restated Employment Agreement between the Company and Hervé Hoppenot, dated as of October 25, 2019 (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019).
	(d)(13)			Offer of Employment Letter, dated April 21, 2023, from the Company to Pablo J. Cagnoni (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023).
	(d)(14)			Registration Rights Agreement, dated as of February 12, 2016, between the Company and 667, L.P., Baker Brothers Life Sciences, L.P. and 14159, L.P. (incorporated by reference to Exhibit 10.28 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2015).
	(d)(15)			Incyte Corporation 2024 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 99.1 to the Company’s Registration Statement on Form S-8 (File No. 333-277043)).
	(d)(16)			Form of Global Nonstatutory Stock Option Agreement for Executive Officers under the Incyte Corporation 2024 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 99.2 to the Company’s Registration Statement on Form S-8 (File No. 333-277043)).
	(d)(17)			Form of Global Restricted Stock Unit Agreement under the Incyte Corporation 2024 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 99.3 to the Company’s Registration Statement on Form S-8 (File No. 333-277043)).
	(d)(18)			Form of Performance Share Award Agreement under the Incyte Corporation 2024 Inducement Stock Incentive Plan (incorporated by reference
	(d)(19)			Stock Purchase Agreement, dated as of May 12, 2024, between the Company and the persons listed in Schedule I thereto (incorporated by reference to Exhibit 10.1 to the Company’s Tender Offer Statement on Schedule TO-C filed with the SEC on May 13, 2024).
	(g)			Not Applicable.
	(h)			Not Applicable.
	107**			Filing Fee Table.

Filed herewith

Filed previously

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

				INCYTE CORPORATION
	Date: May 15, 2024			By:			/s/ Christiana Stamoulis Christiana Stamoulis Executive Vice President and Chief Financial Officer (Principal Financial Officer)

Get the next $INCY alert in real time by email

Date	Price Target	Rating	Analyst
10/29/2024	$68.00 → $90.00	Neutral → Buy	BofA Securities
10/1/2024	$84.00	Outperform	Wolfe Research
9/18/2024	$83.00 → $74.00	Buy → Hold	Truist
7/2/2024	$52.00 → $48.00	Market Perform → Underperform	BMO Capital Markets
5/23/2024	$55.00	Hold	Deutsche Bank
4/23/2024		Neutral	Cantor Fitzgerald
2/23/2024	$81.00	Buy	Jefferies
2/14/2024		Mkt Outperform → Mkt Perform	JMP Securities

SEC Form SC TO-I/A filed by Incyte Corp. (Amendment)

Chat with this insight

Recent Analyst Ratings for $INCY

$INCY SEC Filings

SEC Form 10-Q filed by Incyte Corp.

Incyte Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Incyte Corp.

$INCY FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for JAKAFI issued to INCYTE CORP

FDA Approval for JAKAFI issued to INCYTE CORP

FDA Approval for OPZELURA issued to INCYTE CORP

$INCY Press Releases

Fastest customizable press release news feed in the world

Incyte to Present at Upcoming Investor Conferences

Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte Named One of Top 5 Companies on Science Magazine's 2024 Top Employers List

$INCY Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Incyte Corp.

Amendment: SEC Form SC 13D/A filed by Incyte Corp.

SEC Form SC 13D/A filed by Incyte Corp. (Amendment)

$INCY Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP & General Counsel Denton Sheila A. covered exercise/tax liability with 2,136 shares, decreasing direct ownership by 7% to 30,343 units (SEC Form 4)

EVP, Head of Incyte Intl Heeson Lee was granted 26,447 shares (SEC Form 4)

SEC Form 3 filed by new insider Heeson Lee

$INCY Market Insights

Live Market Insights

S&P 500 Hits Record Highs, Eyes 6th Straight Gain As Powell Keeps Bears At Bay; Tesla Targets 10th Consecutive Win, Bank Stocks Rally: What's Driving Markets Tuesday?

This CrowdStrike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Incyte shares are trading lower after BMO Capital downgraded the stock from Market Perform to Underperform and lowered its price target from $52 to $48.

$INCY Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Incyte upgraded by BofA Securities with a new price target

Wolfe Research initiated coverage on Incyte with a new price target

Incyte downgraded by Truist with a new price target

$INCY Leadership Updates

Live Leadership Updates

$INCY Financials

Live finance-specific insights

Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board

Incyte Names New Member to Its Board of Directors

Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145

Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte to Report Third Quarter Financial Results

Incyte's CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

Recent Analyst Ratings for
$INCY

$INCY
SEC Filings

$INCY
FDA approvals

$INCY
Press Releases

$INCY
Large Ownership Changes

$INCY
Insider Trading

$INCY
Market Insights

$INCY
Analyst Ratings

$INCY
Leadership Updates

$INCY
Financials